N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=4 Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Parkinson Disease
Primary: Maximum Plasma Concentration (Cmax) — 482.98 ng-eq/mL
Phase 1 N=6 AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184 — 251438.3 ng*hr/ml
N/A N=286 A New and Innovative Method for CO2 Removal in Anesthetic Circuits
Anesthesia
Primary: End-tidal CO2 Concentration (%) — 5.069; 5.096 % end-tidal CO2
Phase 4 N=20 Absorption Comparison on Equivalency Value of Genepro Gen2
Analysis, Event History · Absorption; Disorder, Protein
Primary: Weekly Blood Draws to Measure Blood Protein Levels — 7.23; 6.86; 7.43; 7.21 grams per deciliter
Phase 1 N=72 Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Systemic Exposure to Sunscreen Ingredients
Primary: Avobenzone Maximum Concentration — 1.8; 4.3; 4.0; 3.4 ng/mL
Phase 4 N=17 Itraconazole Oral Absorption
Fungal Infection
Primary: AUC — 1624.8; 1365.5; 1282.2; 1848.7 ng*hr/mL
N/A N=186 Evaluation of Micropore"s SpiraLith Absorbents
Airway Management During Operative Procedure
Primary: Duration of Use Under Clinical Anesthesia of Each Absorbent — 1931; 1806; 1527 min
Phase 1 N=5 Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025
Autoimmune Diseases · Fibrosis
Primary: Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV — 5.298; 5.857 Hours
Phase 1 N=6 Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2
Healthy Volunteers
Primary: Absolute Bioavailability of PBT2 (F%) — 15.936 percentage of absolute bioavailability
N/A N=11 Gastric pH and Anthocyanin Absorption
Anthocyanin Metabolism
Primary: Gastric pH — 0.96; 2.31 pH
N/A N=6 Evaluation of the Ability of Newly Developed Adhesives to Absorb Moisture
Stoma Ileostomy
Primary: Resistance (Moisture in the Adhesive) — 0; 0 Number of false positive leaks
Phase 2 N=12 Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans
Healthy
Primary: Plasma Half Life of Labeled Carotenoid — 6.2; 2.3 days
N/A N=6 ABSORB (Amount of Blueberries So Older Adults Reap Benefits)
Depressive Symptoms · Aging
Primary: Urinary Flavonoid Biomarkers — 398863; 1045795 Unitless
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 4 N=25 Cimetidine Biowaivers
Healthy
Primary: AUC — 3896; 3661; 3495; 3512 ng*hr/ml
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 4 N=14 Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
Bile Salt Export Pump (BSEP) Transporter · Polysorbate 80
Primary: Area-Under-the-Curve (AUC) of Pravastatin After Metformin — 264.2; 170.5 ng/ml × h — p=0.02
Phase 1 N=6 Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate — 96.5 ng*h/ml
Phase 1 N=8 A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
Bacterial Enteritis
Primary: The Amounts of Radioactivity Excreted in Urine and Faeces — 78.0; 6.08; 84.1 percentage of administered dose
Phase 1 N=6 A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
Healthy
Primary: Urinary and Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 90.2 percentage of administered radioactivity
N/A N=29 Intra Oral Kinetics of Fluoride Containing Dentifrices
Tooth Erosion
Primary: Concentrations of Fluoride Ions in Saliva 60 Minutes Post Brushing Prior to Administration of the Orange Juice or De-ionised Water Rinse — 0.23; 0.23; 0.15 parts per…
Phase 3 N=4 Sorbent Therapy of the Cutaneous Porphyrias
Erythropoietic Protoporphyria
Primary: Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance — 65.8 minutes
Phase 1 N=12 TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
Healthy Volunteers
Primary: Part 1: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385 — 2.0; 2.0 hours